|
|
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- DDX58/IFIH1-mediated induction of interferon-alpha/beta
- vRNP Assembly
- Regulation of actin dynamics for phagocytic cup formation
- eNOS activation
- Regulation of PLK1 Activity at G2/M Transition
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Sema3A PAK dependent Axon repulsion
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Anchoring of the basal body to the plasma membrane
- Constitutive Signaling by EGFRvIII
- Regulation of necroptotic cell death
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Downregulation of ERBB2 signaling
- ESR-mediated signaling
- Extra-nuclear estrogen signaling
- RHOBTB2 GTPase cycle
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Constitutive Signaling by Overexpressed ERBB2
- Aggrephagy
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
- Potential therapeutics for SARS
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Assembly and release of respiratory syncytial virus (RSV) virions
- Respiratory syncytial virus genome replication
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- Quercetin
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- Tanespimycin
- SNX-5422
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- CCT-018159
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
- Copper
- Polaprezinc
- Alvespimycin
|
|
|
|
HSPA1A |
heat shock protein family A (Hsp70) member 1A |
- Viral RNP Complexes in the Host Cell Nucleus
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Attenuation phase
- HSF1-dependent transactivation
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- Neutrophil degranulation
- PKR-mediated signaling
- Mitochondrial unfolded protein response (UPRmt)
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Attenuation phase
- HSF1-dependent transactivation
- Neutrophil degranulation
- PKR-mediated signaling
- Mitochondrial unfolded protein response (UPRmt)
|
|
|
|
|
HSPBP1 |
HSPA (Hsp70) binding protein 1 |
|
|
|
|
|
HSPH1 |
heat shock protein family H (Hsp110) member 1 |
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- Regulation of HSF1-mediated heat shock response
|
|
|
|
|
HTN3 |
histatin 3 |
|
|
|
|
|
HTT |
huntingtin |
- Regulation of MECP2 expression and activity
|
|
- Huntington's disease (HD)
|
|
|
IL32 |
interleukin 32 |
- Other interleukin signaling
- RAC3 GTPase cycle
|
|
|
|
|
JAK2 |
Janus kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Prolactin receptor signaling
- Prolactin receptor signaling
- Signaling by SCF-KIT
- Signaling by Leptin
- RMTs methylate histone arginines
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF activation
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cyclin D associated events in G1
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- IFNG signaling activates MAPKs
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Factors involved in megakaryocyte development and platelet production
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- XL019
- 5-phenyl-1H-indazol-3-amine
- 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
- 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
- Ruxolitinib
- Tofacitinib
- Pacritinib
- Baricitinib
- Entrectinib
- Fostamatinib
- Fedratinib
- Abrocitinib
- Zanubrutinib
- Pralsetinib
|
|
|
|
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
- Pre-NOTCH Transcription and Translation
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated MAPK activation
- Activation of the AP-1 family of transcription factors
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- MAPK6/MAPK4 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- WNT5:FZD7-mediated leishmania damping
- Signaling by ALK fusions and activated point mutants
- Regulation of PD-L1(CD274) transcription
|
- Adapalene
- Vinblastine
- Pseudoephedrine
- Irbesartan
- Arsenic trioxide
- LGD-1550
|
|
|
|
LALBA |
lactalbumin alpha |
- Lactose synthesis
- Developmental Lineage of Mammary Gland Alveolar Cells
|
|
|
|
|
LINC01554 |
long intergenic non-protein coding RNA 1554 |
|
|
|
|
|
MAPK8 |
mitogen-activated protein kinase 8 |
- Activation of BIM and translocation to mitochondria
- Activation of BMF and translocation to mitochondria
- NRAGE signals death through JNK
- NRAGE signals death through JNK
- NRIF signals cell death from the nucleus
- Oxidative Stress Induced Senescence
- FCERI mediated MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Activation of the AP-1 family of transcription factors
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Interleukin-38 signaling
- WNT5:FZD7-mediated leishmania damping
- Signaling by ALK fusions and activated point mutants
|
- Tamoxifen
- Minocycline
- Pyrazolanthrone
- 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE
- 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
- N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
- 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE
- 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide
- Halicin
|
|
|
|
MAPT |
microtubule associated protein tau |
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
- Flortaucipir F-18
|
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
|
|
|
NEDD8 |
NEDD8 ubiquitin like modifier |
- TGF-beta receptor signaling activates SMADs
- UCH proteinases
- Cargo recognition for clathrin-mediated endocytosis
- Neddylation
- Iron uptake and transport
|
|
|
|
|
NMI |
N-myc and STAT interactor |
- SARS-CoV-1 activates/modulates innate immune responses
|
|
|
|
|
NOA1 |
nitric oxide associated 1 |
|
|
|
|
|
PHC1 |
polyhomeotic homolog 1 |
- Oxidative Stress Induced Senescence
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of transcription cofactors
- SUMOylation of chromatin organization proteins
- SUMOylation of RNA binding proteins
- SUMOylation of DNA methylation proteins
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Transcriptional Regulation by E2F6
|
|
|
|
|
PPID |
peptidylprolyl isomerase D |
|
|
|
|
|
PTEN |
phosphatase and tensin homolog |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Negative regulation of the PI3K/AKT network
- Downstream TCR signaling
- TP53 Regulates Metabolic Genes
- PTEN Loss of Function in Cancer
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Regulation of PTEN mRNA translation
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Transcriptional Regulation by MECP2
|
|
- Vulvar cancer
- Breast cancer
- Malignant melanoma
- Prostate cancer
- Hepatocellular carcinoma
- Small cell lung cancer
- Endometrial Cancer
- Glioma
|
|
|
PTPRF |
protein tyrosine phosphatase receptor type F |
- Receptor-type tyrosine-protein phosphatases
- Insulin receptor recycling
- Synaptic adhesion-like molecules
|
|
|